|
Cập nhật thông tin nghiên cứu dược động học về cơ chế kháng thuốc chống sốt rét
1.Lindegardh, N., Annerberg, A., White, N.J., Day, N.P., (2008), “Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of piperaquine in plasma stable isotope labeled internal standard does not always compensate for matrix effects. J. Chromatogr. B: Analyt”, Technol. Biomed. Life Sci. 862, 227–236. 2.Hanpithakpong, W., Kamanikom, B., Singhasivanon, P., White, N.J., Day, N.P., Lindegardh, N., (2009), “A liquid chromatographic–tandem mass spectrometric method for determination of artemether and its metabolite dihydroartemisinin in human plasma”, Bioanalysis. 2009 Apr;1(1):37-46. 3.Kerb R, Fux R, Morike K, Kremsner PG, Gil JP, Gleiter CH et al., (2009), “Pharmacogenetics of antimalarial drugs: Effect on metabolism and transport”, Lancet Infect Dis 2009; 9: 760-74. 4.Mehlotra RK, Henry-Halldin CN, Zimmerman PA (2009), “Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy”, Pharmacogenomics 2009; 10:435-49. 5.Mendez, F., Herrera, S., Murrain, B., Gutierrez, A., Moreno, L., Manzano, M., Munoz, A., Plowe, C., (2007), “Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine–pyrimethamine treatment and infectivity to anopheles mosquitoes”, Am. J. Trop. Med. Hyg. 77, 438–443. 6.Menemedengue, V., Sahnouni, K., Basco, L., Tahar, R., (2011), “Molecular epidemiology of malaria in Cameroon. XXX. sequence analysis of Plasmodium falciparum ATPase 6, dihydrofolate reductase, and dihydropteroate synthase resistance markers in clinical isolates from children treated with an artesunatesulfadoxine–pyrimethamine combination”, Am. J. Trop. Med. Hyg. 85, 22–25. 7.Mint Lekweiry, K., Ould Mohamed Salem Boukhary, A., Gaillard, T., Wurtz, N., Bogreau, H., Hafid, J.E., Trape, J.-F., Bouchiba, H., Ould Ahmedou Salem, M.S.,Pradines, B., Rogier, C., Basco, L.K., Briolant, S., (2012), “Molecular surveillance of drug-resistant Plasmodium vivax using pvdhfr, pvdhps and pvmdr1 markers in nouakchott, mauritania. J. Antimicrob. Chemother. 67, 367–374. 8.Nelson AL, Purfield A, McDaniel P, Uthaimongkol N, Buathong N, Sriwichai S et al., (2005), “pfmdr1 genotyping and in vivo mefloquine resistance on the Thai-Myanmar border”, Am J Trop Med Hyg; 72: 586-92. 9.Nosten, F., van Vugt, M., Price, R., Luxemburger, C., Thway, K.L., Brockman, A., McGready, R., ter Kuile, F., Looareesuwan, S., White, N.J., (2000), “Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 356, 297–302. 10.Ochong EO, van den Broek IV, Keus K, Nzila A (2003), “Short report: association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan”, Am J Trop Med Hyg 2003; 69: 184-7. 11.Omar SA, Adagu IS, Warhurst DC (2001), “Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure?”, Trans R Soc Trop Med Hyg 2001; 95: 315-9. 12.Dzinjalamala, F.K., Macheso, A., Kublin, J.G., Taylor, T.E., Barnes, K.I., Molyneux, M.E., Plowe, C.V., Smith, P.J., (2005), “Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine–pyrimethamine in Malawian children”, Antimicrob. Agents Chemother. 49, 3601–3606. 13.Ariey F, Fandeur T, Durand R, Randrianarivelojosia M, Jambou R et al., (2006),“Invasion of Africa by a single pfcrt allele of south east Asian type”, Malar. J. 5, 34. 14.Plowe, C.V., (2003), “Monitoring antimalarial drug resistance. making the most of the tools at hand”, J. Exp. Biol. 206, 3745–3752. 15.Roederer MW (2009), “Cytochrome P450 enzymes and genotype-guided drug therapy”, Curr Opin Mol Ther 2009; 11: 632-40. 16.Roper, C., Pearce, R., Bredenkamp, B., Gumede, J., Drakeley, C., Mosha, F., Chandramohan, D., Sharp, B., (2003), “Antifolate antimalarial resistance in southeast Africa: a population-based analysis”, Lancet 361, 1174–1181. 17.Roper, C., Pearce, R., Nair, S., Sharp, B., Nosten, F., Anderson, T., (2004), “Intercontinental spread of pyrimethamine-resistant malaria”, Science 305, 1124-. 18.Sibley, C.H., Hyde, J.E., Sims, P.F.G., Plowe, C.V., Kublin, J.G., Mberu, E.K., Cowman, A.F., Winstanley, P.A., Watkins, W.M., Nzila, A.M., (2001). Pyrimethamine– sulfadoxine resistance in Plasmodium falciparum: what next?” Trends Parasitol. 17, 570–571. 19.White, N.J., Stepniewska, K., Barnes, K., Price, R.N., Simpson, J., (2008), “Simplified antimalarial therapeutic monitoring: using the day-7 drug level?”, Trends Parasitol. 24, 159–163. 20.WHO (2010), Global malaria programme: Q and A antimalarial drug efficacy and drug resistance. http://www.who.int/malaria/resistance.
|
TRANG CHỦ
